Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 1,596 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 1,596 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20. Following the sale, the chief executive officer owned 339,392 shares in the company, valued at $6,431,478.40. This trade represents a 0.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total transaction of $122,441.16.
• On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.78, for a total transaction of $129,675.90.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The stock was sold at an average price of $19.17, for a total transaction of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX traded down $0.38 during trading hours on Friday, hitting $18.41. The company’s stock had a trading volume of 1,190,900 shares, compared to its average volume of 658,370. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $20.25. The stock has a fifty day moving average of $16.98 and a 200-day moving average of $16.27.

Analyst Ratings Changes

BCAX has been the subject of several research analyst reports. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Wedbush restated an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Finally, Citigroup initiated coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicara Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $30.25.

Institutional Investors Weigh In On Bicara Therapeutics

A number of large investors have recently bought and sold shares of BCAX. T. Rowe Price Investment Management Inc. raised its holdings in shares of Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Bicara Therapeutics in the 4th quarter valued at about $44,484,000. Vestal Point Capital LP boosted its stake in shares of Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after purchasing an additional 2,231,025 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $27,265,000. Finally, State Street Corp grew its holdings in shares of Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.